Request for Updated CiteScore

---

Pharmaceutical patent analyst CiteScore Year Wise

Note : This information is taken from the Scopus.

---

Note : This information is taken from the Scopus.

---

Calculation of "Pharmaceutical patent analyst" CiteScore

The CiteScore calculation of the current year depends on the number of citations received by a journal in the last 3 years and the current year aswell, which is then divided by the total number of all documents published in the journal in those last four years (including the calculation year). This is how the cite score of Pharmaceutical patent analyst is calculated. Citescore’s calculation is easy with no secret algorithms or hidden details. The formula for calculation of CiteScore is

CiteScore for 2024 counts the citations received in the year 2024 to documents published in 2021, 2022 and 2023, and divides this by the number of documents published in 2021, 2022 and 2023.

CiteScore is calculated on an annual basis, showing the average citations for a full calendar year but since impact of a journal is dynamic so elsevier provides a cite score tracker that measures performance in real time and provides an updated view of how the journal is performing during the year. CiteScore Tracker is updated every month. So Pharmaceutical patent analyst has its own score card, which is updated monthly.

Issues with CiteScore

Even though when we use CiteScore, it can provide interesting information about how a journal is being cited, its cautioned to be used as a “quality” metricrather than just a journal based metric. One of the immediate implications of CiteScore is that it drastically replaces the measurements of some of the very prestigious publications according to other metrics. This is done by looking at all the parts of the editorial program (editorials, commentaries, perspectives) as articles. CiteScore is used an estimate for research articles, but now it is also being used to judge non-research aspects of journals.

1. We have a new service that is beautifully executed, but adds little value to scholarly communications overall.
2. It puts Elsevier into a conflict of interest instead of being just independent
3. It increases the pressure on the competition.
4. It will encourage a philosophy of editorial design, that will serve the company’s economic and financial interests.

Seeing as how much the use of citescore has been increasing and how journal prestige is being used as an indicator in research evaluation, a critical evaluation of this indicator is thus required. The citescore of Pharmaceutical patent analyst is a very big deal for it.

Pharmaceutical Patent Analyst is dedicated to making the essential content of key patents available in a concise and enriched format to researchers and other specialists, while also providing timely commentary on important issues related to patent and IP law. As one of the main drivers of innovation, in both academia and industry, patents are a rich source of technical information about the latest advances in the discovery and design of novel therapeutics and healthcare products. The journal’s core content therefore comprises high-impact patent reviews that provide an objective and concise appraisal of selected patents in a chosen area, set within the context more...

---